Twice-Rejected Melanoma Drug Gets Surprise FDA Panel Support
Source Summary
RP1 (vusolimogene oderparepvec), a melanoma drug candidate previously rejected twice by the FDA, received unexpected support from an FDA advisory committee panel on Thursday. The decision suggests the drug may have a path forward on its third submission, offering new hope after previous regulatory setbacks.
In depth
RP1, a melanoma immunotherapy candidate, achieved a significant milestone when an FDA advisory committee voted favorably on Thursday, marking a turning point after two previous rejections by the regulatory agency. The drug had faced regulatory hurdles in prior submissions but appears to have gained renewed consideration based on the committee's latest assessment, suggesting that additional clinical or safety data may have addressed earlier concerns and strengthened the case for approval.
